FDA Breakthrough Therapy Designation is a significant regulatory milestone that can accelerate the development and review process of drugs that show substantial improvement over existing therapies on one or more clinically significant endpoints. For Kura Oncology, this designation for Ziftomenib not only validates the drug's potential in treating NPM1-mutant Acute Myeloid Leukemia but also could lead to faster market access. This is likely to have a positive impact on KURA's stock price in the short term as it enhances the company's profile in the biotech industry and among investors, reflecting increased confidence in the company's pipeline and its potential for commercial success.